详情页

当前位置：首页 > 详情页

Hsa_circ_0002496 promotes the growth, angiogenesis, and stemness of breast cancer cells via miR-433-3p/YWHAZ cascade

15| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [2]Department of Tumor Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [3]Department of Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [4]Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

出处：

DOI：

ISSN：

关键词： breast cancer Circ_0002496 miR-433-3p YWHAZ

摘要：

Breast cancer (BC) has been studied more and more in modern medicine. Circ_0002496 has established a critical role in BC. MiR-433-3p can exert important activity in cancer. YWHAZ can participate in BC development, but the targeting relationship among the three variables and its influence on the related process of BC are not clear.RT-qPCR was used to analyze circ_0002496, miR-433-3p, and YWHAZ expression. Immunoblotting was used to analyze YWHAZ, Bax, Bcl-2, and PI3K/AKT-related proteins. RNase R assay was used to verify the ring structure of circ_0002496. Cell phenotypes were tested by Cell Counting Kit 8, EdU, sphere formation, tube formation, and flow cytometry assays.Circ_0002496 was enhanced and MiR-433-3p was downregulated in BC, while the expression of YWHAZ was higher in BC. Circ_0002496 targeted miR-433-3p and miR-433-3p targeted YWHAZ in BC cells. Depletion of circ_0002496 influenced the BC process, but miR-433-3p inhibitor reversed the impact of si-circ_0002496 on the BC process. Re-expression of YWHAZ weakened the influence of miR-433-3p on the BC process. Depletion of circ_0002496 could astrict tumor growth in vivo. Moreover, the circ_0002496/miR-433-3p/YWHAZ axis mediated the activation of the PI3K/AKT signaling pathway.Circ_0002496 participated in the malignant procession of BC by miR-433-3p/YWHAZ regulation cascade.© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 4 区肿瘤学 4 区呼吸系统

最新[2025]版：

大类 | 4 区医学

小类 | 4 区肿瘤学 4 区呼吸系统

JCR分区：

出版当年[2023]版：

Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

最新[2024]版：

Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 2.3 最新[2024版] 2.7 最新五年平均 2.3 出版当年[2023版] 2.8 出版当年五年平均 2.9 出版前一年[2022版] 2.3 出版后一年[2024版]

第一作者：

第一作者机构： [1]Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

通讯作者：

通讯机构： [1]Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [*1]Department of Breast Center, the Fourth Hospital of Hebei Medical University, No. 169 Tianshan Street, Shijiazhuang, Hebei, 050000, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]LncRNA IGFL2-AS1 as a ceRNA Promotes HCT116 Cell Malignant Proliferation via the miR-433-3p/PAK4 Axis [2]Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer [3]Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain:MDAnderson Cancer Center experience [4]Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo [5]Breast Cancer and Lipid Metabolism [6]Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021. [7]An integrated Chinese society of clinical oncology of breast cancer (CSCO BC) database from 45809 Chinese breast cancer patients [8]Endocrine resistance in breast cancer [9]Clinicopathological characteristics and prognosis of breast cancer patients with lung cancer: A study based on 19,807 breast cancer patients. [10]A new model to prognosticate man breast cancer in China